Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer-Reference-Cited by-同舟云学术

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Published:2019-09-03 Issue:5 Volume:84 Page:1003-1015
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Gueorguieva Ivelina,Tabernero Josep,Melisi Davide,Macarulla Teresa,Merz Valeria,Waterhouse Timothy H.,Miles Colin,Lahn Michael M.,Cleverly Ann,Benhadji Karim A.

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03931-1.pdf

Reference29 articles.

1. Ahmed S, Bradshaw AD, Gera S, Dewan MZ, Xu R (2017) The TGF-beta/Smad4 signaling pathway in pancreatic carcinogenesis and its clinical significance. J Clin Med. https://doi.org/10.3390/jcm6010005

2. Smith AL, Robin TP, Ford HL (2012) Molecular pathways: targeting the TGF-beta pathway for cancer therapy. Clin Cancer Res 18:4514–4521. https://doi.org/10.1158/1078-0432.CCR-11-3224

3. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A (2015) Targeting the TGFbeta pathway for cancer therapy. Pharmacol Ther 147:22–31. https://doi.org/10.1016/j.pharmthera.2014.11.001